secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-10-19T12:08:31+00:00
Accession:  0001104659-26-116736
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ArriVent firmonertinib FURTHER Phase 1b data published in Cancer Cell: ORR 43-68% in EGFR PACC NSCLC
--------------------------------------------------------------------------------

- Confirmed ORR 43% at 160 mg and 68% at 240 mg, with median PFS of 11.1 and 16.0 months by BICR in front-line EGFR PACC-mutant NSCLC.
- Intracranial ORR of 47% (8/17), including 41% complete responses, among 17 patients with baseline brain metastases.
- 80% of evaluable patients achieved complete ctDNA molecular response by cycle 3; those patients showed ORR 70% vs 20% and PFS 15.1 vs 3.0 months.
- EGFR PACC mutations are ~12% of EGFR-mutant tumors with no established targeted standard of care; firmonertinib showed enhanced in vitro potency vs osimertinib.
- Global Phase 3 ALPACCA trial (FURMO-006; NCT07185997) is enrolling, testing firmonertinib vs investigator's choice of osimertinib or afatinib in first-line disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/0001104659-26-116736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/tm2627799d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-116736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer